| Literature DB >> 35659262 |
Emiri Muranaka1,2, Ryota Hase3,4, Yoshikazu Utsu5, Tomohisa Watari6, Yoshihito Otsuka6, Naoto Hosokawa4.
Abstract
BACKGROUND: Catheter-related bloodstream infection (CRBSI), caused by rapidly growing mycobacteria (RGM), is a rare infectious complication in hematopoietic stem cell transplant (HSCT) recipients and can often be misdiagnosed as Gram-positive rod (GPR) bacteremia. CASEEntities:
Keywords: Case report; Mycobacterium wolinskyi; Rapidly growing mycobacteria; Umbilical cord blood transplant; Unidentifiable Gram-positive rods
Mesh:
Year: 2022 PMID: 35659262 PMCID: PMC9167550 DOI: 10.1186/s12879-022-07495-z
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.667
Fig. 1Left Gram staining of blood cultures shows diphtheroid bacilli and short branching filaments. Right Ziehl–Neelsen staining of colonies obtained by subculture
Results of antimicrobial susceptibility testing of Mycobacterium wolinskyi isolated in our case
| Antibiotic | MIC (mg/mL) | S ≤ | I | R > |
|---|---|---|---|---|
| Amikacin | ≤ 4 | 16 | 32 | 64 |
| Tobramycin | > 16 | 4 | 8–16 | 32 |
| Imipenem | 16 | 4 | 8–16 | 32 |
| Levofloxacin | 2 | 2 | 4 | 8 |
| Moxifloxacin | 1 | 1 | 2 | 4 |
| Clarithromycin | 64 | 2 | 4 | 8 |
| Trimethoprim–sulfamethoxazole | 152/8 | 38/2 | No | 76/4 |
| Doxycycline | ≤ 0.5 | 1 | 2–8 | 16 |
| Linezolid | 2 | 8 | 16 | 32 |
MIC minimum inhibitory concentration, S susceptible, I intermediate, R resistant
Summary of published cases of M. wolinskyi bacteremia
| Age | Gender | Comorbidities | Type of infection | Treatment | Intravascular devices | Device removal | Gram stain | Outcome | Time to positive blood culture (days) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Chen et al. [ | 22 | f | NHL on chemotherapy | BSI/septic arthritis in native joint | Surgical debridement + AMK (1 month), MXF and MIN (6 months) | Venous port | Yes | N/A | N/A | 3 |
| Ohno et al. [ | 55 | f | CML on chemotherapy | BSI No source identified | AMK (1 month), MIN and LVX (6 months) | None | N/A | GPR | Good outcome at 1.5-year follow-up | 5 |
| Ariza-Heredia et al. [ | 16 | m | Congenital aortic stenosis status post-Ross procedure | BSI, likely endocarditis and infected aortic root graft | AMK, MXF and DOXY (ongoing) | Vascular graft | Yes | N/A | Underwent pulmonary artery conduit replacement | 5 |
| Kitajima et al. [ | 82 | m | Status-post AVR and MVR | Prosthetic valve endocarditis | AMK, IPM and CLR (6 weeks) then CIP and MIN (total 12 months) | Prosthetic valve | No | GPR | Cure | 5 |
| Present case | 43 | f | AML post hematopoietic stem cell transplantation | Catheter related blood stream infection | AMK, IPM/CS, LVX and AZM (6 days) AMK, IPM/CS, LVX and MIN (13 days), AMK, MXF and MIN (15 days) then MXF (4 months) and MIN (6 months) | PICC | Yes | GPR | Cure | 2 |
NHL non-Hodgkin lymphoma, CML chronic myeloid leukemia, AVR aortic valve replacement, MVR mitral valve replacement, AML acute myeloid leukemia, BSI bloodstream infection, AMK amikacin, MXF moxifloxacin, MIN minocycline, LVX levofloxacin, IPM imipenem, CLR clarithromycin, CIP ciprofloxacin, AZM azithromycin, PICC peripherally inserted central catheter, IPM/CS imipenem/cilastatin, N/A not available, GPR Gram-positive rod